MapLight’s schizophrenia drug disappoints once-daily hopes despite Phase 2 win

MapLight dives despite positive data for schizophrenia drug

MapLight's schizophrenia drug achieved 4.5-point PANSS gain; stock fell 66% as investors compared it to Bristol Myers' Cobenfy (8.4-9.6). MapLight's better profile—no fasting, 19.9% vs. 28% discontinuation—shows tolerability can offset efficacy gaps in drug competition.